Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Awakn Life Sciences Corp (OP: AWKNF )

0.1911 -0.0223 (-10.45%)
Streaming Delayed Price Updated: 3:50 PM EDT, Jun 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Awakn Life Sciences Corp

< Previous 1 2 3 4 Next >
These 18 Clinical Trials Could Shape The Future Of The Psychedelics Industry
In the nascent industry of medical psychedelics, drug development is the name of the game. This subset of biotech, poised to become a $100 billion industry according to Canaccord Genuity, bases its... 
Via Benzinga
Psyched: Medical Psychedelics In Davos, Canadian Sen Does Psychedelics, Ei.Ventures & Mycotopia To Merge Into $383M Company
Medical Psychedelics have made it into Davos, just in time for the World Economic Forum. 
Via Benzinga
Awakn Life Sciences Reports Completing World's First Ketamine Study For A Range Of Behavioral Addictions
Photo by Tranava University on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Could Ketamine be a... 
Via Benzinga
Awakn's Study On Psychedelics For Treating Addiction Shows Promise, Will Undertake Broader Research
Awakn Life Sciences (OTCQB: AWKNF) has announced the successful completion of the first ketamine study for a varied set of behavioral addictions. 
Via Benzinga
Wake-Up Call: This Biotech Company Is Using Psychedelics To Treat Addiction
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
Core One Labs Begins Trading On OTCQB
Under the CLABF symbol, psychedelics-oriented company Core One Labs (OTCQB: CLABF) started trading on the OTCQB Venture ... 
Via Benzinga
Psyched: Atai, MindMed, Enveric and Mydecine Release 2021 Earnings, Bienstar Expands To Brazil & More!
It’s earnings week in the psychedelics space, opening a new window into the financial situations of many companies in the sector. 
Via Benzinga
Stifel Initiates Coverage On Awakn Life Sciences With A Speculative Buy, $8 Target Price Target
Awakn Life Sciences (OTC: AWKNF) is in the news after a respected analyst has upgraded the stock.  Awakn is a publicly traded company which trades on the over-the-counter market with the symbol of  
Via Benzinga
This Biotech Company Is Landing Ketamine-Assisted Therapy In England's Capital
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. As it pushes ahead with expansion into the United States,... 
Via Benzinga
Awakn Life Sciences Seeks To Treat Addictions: Gambling, Binge Eating And Compulsive Sexual Behavior
Awakn Life Sciences (OTC: AWKNF) is not only going after alcoholism but also binge eating disorder, compulsive sexual behavior and even Internet gaming disorder. 
Via Benzinga
This Ketamine-Assisted Therapy Company Is Developing New Ways To Treat Alcohol Addiction
Picture credit: Martin Sanchez on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
Psychedelic And Cannabis Drug Stocks Continue Advance
This article updates the performances of 16 clinical-stage psychedelic and marijuana drug companies researching the treatment of a wide variety of mental illnesses. 
Via Talk Markets
Mindset Pharma, Cybin Among Top Psychedelic Movers Of Today
GAINERS: Awakn Life Sciences (OTC:AWKNF) shares closed up 3.51% at $1.62 
Via Benzinga
Mind Medicine, Allied Among Top Psychedelic Movers Of Today
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 5.04% at $0.17 
Via Benzinga
Has A Sugar Daddy Emerged In The Psychedelic Drug Industry?
One very large drug multinational has already been active in writing checks to finance drug development in the psychedelic drug industry. 
Via Talk Markets
The Psychedelic & Marijuana Drug Stocks Index Dropped -30% In January
This article updates the performances of 16 clinical-stage psychedelic and marijuana drug companies researching the treatment of a wide variety of mental illnesses. 
Via Talk Markets
Mind Medicine, Small Pharma Among Top Psychedelic Movers Of Today
GAINERS: Mindset Pharma (OTC:MSSTF) shares closed up 6.29% at $0.49 
Via Benzinga
Psychedelic Stock Gainers And Losers From January 24, 2022
GAINERS: Field Trip Health (NASDAQ: 
Via Benzinga
Psychedelic Stock Gainers And Losers From January 21, 2022
GAINERS: GH Research (NASDAQ: 
Via Benzinga
Psychedelic Stock Gainers And Losers From January 20, 2022
GAINERS: Small Pharma (OTC: 
Via Benzinga
Revive Therapeutics, GH Research Among Top Psychedelic Movers Of Today
GAINERS: Revive Therapeutics (OTC: 
Via Benzinga
Psychedelic Stock Gainers And Losers From January 18, 2022
GAINERS: Cybin (AMEX: 
Via Benzinga
Psyched: Delix Raises $30M, New Ketamine Study For Alcohol Use Disorder, FDA Approves Ketamine Trial For ALS
New Awakn Study Shows Ketamine Has Potential To Treat Alcoholism Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: 
Via Benzinga
Ketamine Therapy Shows Potential In Treatment Of Alcohol Use Disorder, New Study Finds
Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB:AWKNF) publis... 
Via Benzinga
The Year In Review For Psychedelic Drug Stocks: 2021
2021 was two different 
Via Talk Markets
Marijuana & Psychedelic Compounds-Based Drug Stocks Now Down -16% YTD
A look at which index has done the best so far in December: the Marijuana Drug Stocks Index or the Psychedelic Compounds-Based Drug Stocks Index. 
Via Talk Markets
AWKNF: A Psychedelic's Stock Exhibiting Recent Price Appreciation
Awakn Health Sciences Corp's trading pattern over the past 10-day time span is an egregious example of a psychedelic stock that has exhibited recent price appreciation coupled with a surge in average... 
Via Talk Markets
Psychedelic Drug Stocks Continued To Decline Last Week
The 12 constituents in our Pure-Play Psychedelic Compounds-Based Drug Stocks Index declined -5.7% last week; it's now -16.1% so far in November. 
Via Talk Markets
New Options to Treat Alcohol Use Disorder
New Options to Treat Alcohol Use Disorder 
Via News Direct
Psychedelic Drug Stocks Have Plunged -10.6%, On Average, So Far In November
Our Pure-Play Psychedelic Compounds-Based Drug Stocks Index has declined -10.6% in the last 2 weeks; it's still up +7.8% since the end of September. 
Via Talk Markets
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.